Mapp Biopharmaceutical, Inc

Name of License: 
Mapp Biopharmaceutical, Inc
By the: 
U.S. Army Medical Research & Development Command - Medical Technology Transfer Office (MTT)
On: 
Dec 07, 2020
Summary 

In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license.

Tech Name: 
Purified, Recombinant, Catalytically Inactive Botulinum Neurotoxin Holoproteins
Action: 
Intent
Dates: 
The deadline to receive comments is December 21, 2020.
Address: 
Commander, U.S. Army Medical Research and Development Command, ATTN: Director, Office of Research and Technology Applications, 1520 Freedman Drive, Suite 227, Fort Detrick, MD 21702-5012.
For further information contact 

Dr. Paul Michaels, Director of the Office of Research & Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory Patent Attorney, (301) 619-7808.

Supplementary information 

In accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license to “purified, recombinant, catalytically inactive botulinum neurotoxin holoproteins (ciBoNT) representing serotypes A-F produced in transgenic strains of the methylotrophic yeast Pichia pastoris, and Pichia pastoris cell lines expressing the same ciBoNTs, in their capacity as producers of the ciBoNTs only” to Mapp Biopharmaceutical, Inc., having its principal place of business at 6160 Lusk Blvd. # C200, San Diego, CA 92121.

Anyone wishing to object to grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Director, Office of Research and Technology Applications (see ADDRESSES).

Upload PDF: 
PDF icon flc_business_notice_mapp_biopharmaceuticals_12-07-20201.pdf